Trials are also examining the effects of novel therapeutic immune agents, including an antagonistic OX40 monoclonal antibody (NCT01862900) and the STING agonist TAK-676 (NCT04879849) combined with radiotherapy for the treatment of breast cancer patients. This evidence concerns the gene TNFRSF4 and breast carcinoma.